Search results for: France
Filter search results
Challenges and Solutions for Budget Impact Analysis of Gene Therapies
10 March 2025
…considered in detail. This report reviews the current approaches to and use of BIA in the context of gene therapies across a selection of European countries: Belgium, England, Denmark, France,…
Analysing Global Immunisation Expenditure
15 April 2025
…and coverage over the period of 2016 to 2022 across ten countries (Australia, Brazil, Canada, France, Germany, Italy, Japan, Mexico, South Korea and the United Kingdom). Key Findings Low spending…
OHE submission to the UK Parliamentary Inquiry on an Ageing Society
20 May 2025
…and vaccine schedules: Australia, Brazil, France, Germany, Italy, Japan, Poland, South Africa, Thailand, and the United States. Our research concluded that adult vaccines can return up to 19 times their initial…
2022 Innovation Policy Prize
…A price that is no barrier to access to an insured patient in France may be unaffordable for patients (and insurers) in Bulgaria. High prices often inhibit access to drugs for rare diseases…
The commercial case for investing in ALS
13 November 2025
…for investing in ALS research and therapeutic development, highlighting the unmet need, socioeconomic burden, and market opportunity across seven major countries: the UK, US, Canada, France, Germany, Italy, and Australia….
A global landscape analysis of access to tumour-agnostic therapies
1 December 2025
…a landscape analysis of access to TA therapies across 11 countries – Australia, Brazil, Canada, China, France, Germany, Italy, Japan, Spain, the UK, and the US. It focuses on three…
Capturing the lived experiences of informal care in acute leukemia
20 November 2025
…quality of life, we spoke to 60 informal carers, 20 from European Union countries – including 5 each from France, Germany, Italy and Spain – and 20 each from the…
Biosimilars’ Price Dynamic in Europe
30 June 2010
…seminar and summarises the remarks of Dr Matthias Liefner of Simon Kucher and Partners. In Europe, pricing of biosimilars already has begun to affect the market for biologics. For example, France’s compulsory…
OHE at ISPOR Europe 2: Conceptual and Practical Challenges in Judging Value
29 October 2014
…Santé in France; NICE in England and Wales; and Aetna, a private health insurance company in the US. These three were selected to suggest how assessment approaches might differ in…